Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Protective effect of ulinastatin against colistin-induced acute kidney injury in severe pneumonia
KCT0005684Phase 4Not yet recruiting
- Sponsor
- Hanlim Pharm
- Start
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of ulinastatin in pneumonia, acute kidney failure (AKF), sponsored by Hanlim Pharm. Planned start Dec 2020; status: not yet recruiting.
02
Drugs
ulinastatin
03
Conditions
pneumoniaacute kidney failure (AKF)
Beyond the preview
Go deeper on KCT0005684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005684.